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ABSTRACT
Cell communication is central to the integration of cell function required for the
development and homeostasis of multicellular animals. Proteins are an important
currency of cell communication, acting locally (auto-, juxta-, or paracrine) or
systemically (endocrine). The fibroblast growth factor (FGF) family contributes to
the regulation of virtually all aspects of development and organogenesis, and after
birth to tissue maintenance, as well as particular aspects of organism physiology.
In the West, oncology has been the focus of translation of FGF research, whereas in
China and to an extent Japan a major focus has been to use FGFs in repair and
regeneration settings. These differences have their roots in research history and aims.
The Chinese drive into biotechnology and the delivery of engineered clinical grade
FGFs by a major Chinese research group were important enablers in this respect.
The Chinese language clinical literature is not widely accessible. To put this into
context, we provide the essential molecular and functional background to the FGF
communication system covering FGF ligands, the heparan sulfate and Klotho
co-receptors and FGF receptor (FGFR) tyrosine kinases. We then summarise a
selection of clinical reports that demonstrate the efficacy of engineered recombinant
FGF ligands in treating a wide range of conditions that require tissue
repair/regeneration. Alongside, the functional reasons why application of exogenous
FGF ligands does not lead to cancers are described. Together, this highlights that the
FGF ligands represent a major opportunity for clinical translation that has been
largely overlooked in the West.
Subjects Biochemistry, Drugs and devices, Surgery and surgical specialties, Translational medicine
Keywords Wound, Fibroblast growth factor, Ulcer, Fibroblast growth factor receptor, Heparan
sulfate, Klotho, Healing, Protein therapeutic, Tissue repair
OVERVIEW
In unicellular organisms the unit of natural selection is the cell, whereas in multicellular
animals natural selection operates on the organism. This is a very profound difference.
The driver is likely to have been simple: there is a limit on the complexity of an individual
cell, beyond which it is no longer robust. However, greater organism complexity allows
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new ecological niches and lifestyles to be exploited. Natural selection has given rise to
multicellularity and cell specialisation, as a means to allow a high level of organism
complexity in concert with simple and robust cells. This requires a deep functional
integration of cells in the organism, achieved through cell communication, which occurs
by cells delivering information through the synthesis and secretion of signalling molecules
into the extracellular space; these then elicit signals in cells possessing appropriate receptor
systems. The entire biochemical landscape, from ions and small molecules to proteins and
polysaccharides is used to generate the repertoire of signalling molecules.
In multicellular animals, proteins are common currency in cell communication and are
used to transmit information between cells in the organism both locally (intra-,
auto-, juxta- and paracrine) and systemically (endocrine). Local transmission of
information may be mediated by a soluble, secreted protein, or by a protein anchored in
the extracellular matrix or on the plasma membrane of a neighbouring cell. The
exploitation of proteins for cell communication by multicellular animals provides access
to a very subtle language. This subtlety arises in part from the fact that an individual
protein species may have many different isoforms (from splice variants to glycoforms),
localisations and interacting partners. Each subset of molecular interactions that an
individual protein species can partake in may elicit completely different, sometimes
opposing, cellular responses, and, moreover, may change the distance over which
communication occurs, e.g., paracrine versus endocrine.
Most therapeutics can be considered to manipulate cell communication, with varying
aims, such as reducing overactive communication channels in cancer and inflammatory
diseases, or increasing particular channels of communication for tissue repair and
regeneration. Clearly, manipulating cell communication therapeutically is not without
danger, since the opposite of the desired effect may occur. Less obvious, but an important
focus of this review, is that the drivers of scientific discovery can narrow dramatically how
a particular communication system is used clinically. This is exemplified by the fibroblast
growth factor (FGF) family, which contributes to the regulation of virtually all aspects of
development and organogenesis, and after birth in many natural processes of tissue repair
and the endocrine regulation of particular facets of organism physiology. In the West, the
major focus of clinical translation has been on developing inhibitors of FGF-mediated cell
communication for use in cancer therapy. In the East, particularly in China and to an
extent in Japan, a major focus has been to use FGFs in regenerative/repair medical
settings, differences that have their roots in a combination of research history and
research aims. To increase awareness of this work, we summarise a number
of published clinical reports to illustrate the breadth and depth of the successful
clinical applications of FGFs.
THE DISCOVERY OF FGF LIGANDS AND
THEIR ACTIVITIES
Historically, the growth factor activity was the first to be identified. In hindsight, the paper
of Trowell & Willmer (1939), which measured the mitogenic activity of saline extracts of
different tissues from the chick can be considered to be the first FGF paper
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(Trowell & Willmer, 1939)–the activity they isolated from brain would consist of FGF-1,
FGF-2 (Burgess &Maciag, 1989), as well as other growth factors active on fibroblasts, (e.g.,
pleiotrophin (Courty et al., 1991)), and that from other tissues largely FGF-2 (Burgess &
Maciag, 1989; Fernig & Gallagher, 1994). Over 30 years later a growth factor activity that
stimulated the growth of a fibroblast cell line was identified in partially purified extracts
from bovine pituitary. It was called “fibroblast growth factor”, simply due to the assay used
to measure activity (Rudland, Seifert & Gospodarowicz, 1974). Though an unsatisfactory
name, because FGFs do far more than stimulate fibroblast growth and in a considerable
number of instances they do not even possess this activity, the label has stuck (see
Burgess & Maciag, 1989) for other early names and a brief overview of the discovery of
FGF-1 and FGF-2). A great deal of the early work on FGFs, including that of (Trowell &
Willmer, 1939), was from a cancer perspective, driven by the idea that uncontrolled
proliferation is a hallmark of cancers and so growth factors must have a key role to play.
Moreover, the ambition to cure cancers provided funding for this and much subsequent
work on FGFs and other growth factors. This was not misplaced, since the analysis of
experimental tumours and of activities capable of transforming cells in vitro enabled the
discovery of some, but not all of FGFs -3 to -9 (summarised in Burgess & Maciag (1989) &
Fernig & Gallagher (1994)) and there are a number of successful FGF receptor (FGFR)
inhibitors in oncology (Carter, Fearon & Grose, 2015; Turner & Grose, 2010).
The interaction with heparin was key to the successful purification of FGF-1 and -2
(Maciag et al., 1984; Shing et al., 1984), and was translated into work on the interaction of
these FGFs with the glycosaminoglycan heparan sulfate (HS) in the pericellular and
extracellular matrix (e.g., Vlodavsky et al., 1987). The FGF receptor (FGFR) tyrosine
kinases were then identified and, soon after, the dependence of the growth factor activity
of FGFs on heparan sulfate (Rapraeger, Krufka & Olwin, 1991; Yayon et al., 1991) was
discovered. This provided a framework within which to understand function, heparan
sulfate controlled the transport of FGFs between cells and was a part of a dual receptor
(heparan sulfate + FGFR) signalling system. Subsequently, some FGFs were found to not
bind heparan sulfate, but to interact with a protein co-receptor, Klotho; these FGFs do not
elicit a growth factor response, but instead are endocrine hormones (Belov &
Mohammadi, 2013; Kuro-o et al., 1997; Martin, David & Quarles, 2012). A further set of
FGF proteins, the FGF homology factors or FHFs, are wholly intracellular and do not
interact with any of the extracellular receptors and partners of FGFs. As such they are not
directly part of the FGF cell communication system and lie outside the scope of this review
(for review see Goldfarb, 2005).
THE FGF COMMUNICATION SYSTEM: MOLECULES
AND STRUCTURE
The core of the FGF communication system comprises a family of ligands, the FGFs,
a family of cell surface signal transducing receptors, the FGFRs, and two distinct
co-receptors, the Klothos and the glycosaminoglycan heparan sulfate, which is the
physiologically relevant polysaccharide; heparin is often used as its experimental proxy,
but has important structural differences.
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The FGF ligand family
Phylogenetic analysis of human protein sequences indicates that there are seven FGF
subfamilies: FGF1 and FGF2 (FGF1 subfamily); FGF4, FGF5 and FGF6 (FGF4 subfamily);
FGF3, FGF7, FGF10 and FGF22 (FGF7 subfamily); FGF8, FGF17 and FGF18 (FGF8
subfamily); FGF9, FGF16 and FGF20 (FGF9 subfamily); FGF11, FGF12, FGF13 and
FGF14 (FGF11 subfamily); FGF19, FGF21, and FGF23 (FGF19 subfamily) (Fig. 1).
The members of FGF8, FGF9, FGF11 and FGF19 subfamilies are consistent between the
phylogenetic analysis and the gene location analysis. However, FGF5 and FGF3 are
indicated to be members of FGF4 and FGF7 subfamilies by the analysis of gene location on
chromosomes (Horton et al., 2003; Itoh, 2007; Itoh & Ornitz, 2008; Itoh & Ornitz, 2011).
The phylogenetic relationship based on sequence maps to functional similarities of the
FGFs (Ornitz et al., 1996; Xu et al., 2013; Zhang et al., 2006) and it is in this context that
FGF subfamilies will be discussed here.
FGF ligand structure
The molecular weight of FGFs range from 17 to 34 kDa in vertebrates, whereas it reaches
to 84 kDa in Drosophila. All FGFs share an internal core of similarity with 28 highly
conserved, and six invariant amino acid residues (Ornitz, 2000). X-ray crystallography of
FGFs shows that the FGF family possesses a similar folding pattern to the interleukins
Figure 1 Phylogenetic relationship of the FGFs based on amino acid sequence. According to amino
acid sequence, dendroscope was used to show that FGF family is divided into seven subfamilies.
The branch lengths relates directly to the evolutionary relationship of FGFs.
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IL-1b and IL-1a (Zhu et al., 1991), a b trefoil structure, formed by three sets (Fig. 2A) of
four b strands connected by loops (Fig. 2B) (Zhang et al., 1991). A variety of studies have
demonstrated that the primary heparan sulfate binding site of FGF2 is formed by the
strand b1/b2 loop, strands b10/b11 loop, strand b11 and strands b11/b12 loop (Fig. 3B)
(Baird et al., 1988; Faham et al., 1996; Li et al., 1994; Thompson, Pantoliano & Springer,
1994; Zhang et al., 1991). The receptor binding site involves the strands b8-b9 loop and is
distinct from the primary heparan sulfate binding site (Figs. 3A and 3B). This indicates
that the binding to receptor and to heparan sulfate are physically separated (Itoh & Ornitz,
2004; Ornitz & Itoh, 2001; Zhang et al., 1991). Secondary heparan sulfate binding sites
are also present in many FGFs and their position on the surface of the ligands may
follow their sequence phylogenetic relationship (Ori et al., 2009; Xu et al., 2012)
(Figs. 3B and 3C).
Receptors: Heparan sulfate and FGFR
Heparan sulfate
Proteoglycans are O-glycosylated proteins, such as perlecan, glypicans and syndecans
(Taylor & Gallo, 2006; Yung & Chan, 2007). The heparan sulfate chains bind and regulate
the function of over 435 extracellular proteins, including the paracrine FGFs (Gallagher,
2015; Ori, Wilkinson & Fernig, 2008; Ori, Wilkinson & Fernig, 2011; Xu & Esko, 2014). The
proteoglycan core proteins are synthesized on the rough endoplasmic reticulum and then
transported to the Golgi apparatus where the glycosaminoglycan chains are synthesised
(Yanagishita & Hascall, 1992). The glycosaminoglycan chains are linear polysaccharides
mainly consisting of repeating disaccharide units (Fig. 4A) (Gallagher, 2015; Ori,
Wilkinson & Fernig, 2008; Taylor & Gallo, 2006; Xu & Esko, 2014). The members of the
glycosaminoglycan family are heparan sulfate, chondroitin sulfate (CS), dermatan sulfate
(DS), hyaluronan (HA) and keratan sulfate (KS) (Delehedde et al., 2001).
Figure 2 Schematic diagram of the core structure unit of the beta-trefoil. PDB ID: 2FGF (Zhang et al.,
1991). (A) The first ascending strand (bA) is connected to a descending strand (bB). The following
“horizontal” strand (bC) finishes by returns strand (bD). (B) Three of these units arranged around a
pseudo three-fold axis of symmetry form the b trefoil.
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Heparan sulfate is made of repeating disaccharide units of glucuronic acid linked
to N-acetylglucosamine (Fig. 4A). In the Golgi apparatus, the synthesis of heparan
sulfate chains is started by the assembly of a tetrasaccharide linkage onto
a serine residue of the core protein by four enzymes acting sequentially
(Xyl transferase, Gal transferase I and II and GalA transferase); the repeat disaccharide
(A) 
(B) (C) 
HBS1 
HBS1 
HBS2 HBS3 
Figure 3 FGF interactions with FGFR and heparin/heparan sulfate. (A) Ternary structure of
FGF-FGFR-heparin complex (1FQ9 (Schlessinger et al., 2000)). FGFs interact with the D2 andD3 domain
and the linker between these two domains. A heparin octasaccharide, binds to the conserved canonical
binding site on FGFs, which is opposite to the N-terminal, and to the basic canyon in the FGFR.
(B) Heparin binding sites of FGF2 (1FQ9) identified by a selective labelling approach (Ori et al., 2009).
Three binding sites were recognised: the canonical binding site (HBS1), and two secondary and relatively
weaker binding sites (HBS2 and HBS3). (C) Heparin binding site of FGF9 (1G82 (Hecht et al., 2001)).
Only the conservedHBS1 was identified, indicating that FGF9 does not possess secondary polysaccharide
binding sites (Xu et al., 2012), subsequently confirmed in biophysical experiments (Migliorini et al., 2015).
Green indicates the N-terminal of the proteins. Grey is FGFR1. Magenta are FGFs (FGF2 in B and FGF9
in C). The residues in blue are the heparin binding sites of the FGFs.
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units, (4-GlcA b1–4 GlcNacb1-)n (where n ∼25 to 100) are then added by the
copolymerases EXT1 and EXT2 (Dreyfuss et al., 2009; Lin, 2004; Tumova,
Woods & Couchman, 2000). After the synthesis of the chain, clusters of N-acetyl
glucosamine are removed and N-sulfate groups are added by the dual activity
N-deacetylase-N-sulfotransferases (NDSTs) (Dreyfuss et al., 2009; Lin, 2004; Tumova,
Woods & Couchman, 2000). The subsequent modifications are on N-sulfated
glucosamine containing disaccharides or their neighbours: an epimerase converts
NA S
(A)
(B)
Core protein
Linkage
NAS NA SNASNAS
Variable sulfaon structure 
Figure 4 Structures of disaccharide units of HS and heparin. (A) Structure of disaccharide unit of
heparin/HS. Top: the glucuronic acid containing disaccharide. This is generally not or only slightly
modified by sulfation (in red). Bottom: the iduronic acid containing disaccharide, which always contains
an N-sulfated glucosamine (red) and is often further modified by O-sulfation (red). (B) Structure of HS
chains. The polysaccharide chain is covalently linked to a serine on the proteoglycan core protein.
The sulfate groups are added by sulfotransferases after the GAG chain is polymerised. Due to the
hierachical dependence of the post polymerisation reactions and the sulfation of discrete blocks of
N-acetylglucosamines by N-deacetylase-N-sulfotransferases (NDSTs), the HS chain has a domain
structure of alternating NA (GlcA/GlcNAc), NAS (∼one disaccharide in two is N-sulfated) and S (every
glucosamine is N-sulfated) domains. Chain lengths vary from ∼25 disaccharides to over 100. Heparin, a
common experimental proxy for heparan sulfate is ∼30 disaccharides in length and can be considered to
be a highly sulfated NS domain.
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glucuronic acid to iduronic acid, which may then be 2-O sulfated and the glucosamine
may be 6-O and 3-O sulfated (Dreyfuss et al., 2009; Lin, 2004; Tumova, Woods &
Couchman, 2000).
Since NDSTs selectively act on blocks of disaccharides, the modified heparan sulfate has
a domain structure of NA, NAS domain and S domains (Fig. 4B) (Connell & Lortat-Jacob,
2013; Dreyfuss et al., 2009; Gallagher, 2015; Murphy et al., 2004; Ori, Wilkinson & Fernig,
2008). Differences in sulfation level of the NAS and NS domains provide the means for
heparan sulfate to bind with varying degrees of selectivity to over 435 proteins (Ori,
Wilkinson & Fernig, 2008; Xu & Esko, 2014), including FGFs binding S-domains and
antithrombin III binding transition domains (Turnbull, Powell & Guimond, 2001; Xu &
Esko, 2014). Since the modification reactions by the sulfotransferases do not go to
completion, the length and level of sulfation of heparan sulfate chains are also variable in
different cells and extracellular matrices (Dreyfuss et al., 2009; Kirkpatrick & Selleck, 2007;
Ori, Wilkinson & Fernig, 2008; Xu & Esko, 2014).
FGFR
FGFRs, spanning the membrane, are the key to transferring induced signals into the cell,
which direct the target cell activities, such as cell proliferation, differentiation and
migration (Beenken & Mohammadi, 2009; Ornitz, 2000; Turner & Grose, 2010). Five
different FGFRs (FGFR1–4 and FGFRL1) and many of their alternative spliced isoforms
have been found to bind with FGFs and activate a large number of signalling pathways
(Dorey & Amaya, 2010; Itoh & Ornitz, 2011; Turner & Grose, 2010; Wiedemann & Trueb,
2000). FGFR1–4 possess three extracellular immunoglobulin-like loops, I, II and III (often
termed D1, D2 and D3), a transmembrane linker and a cytoplasmic kinase domain
(Beenken & Mohammadi, 2009; Dorey & Amaya, 2010; Goetz & Mohammadi, 2013;
Turner & Grose, 2010). FGFRL1 differs in that its intracellular domain lacks a tyrosine
kinase (Kim et al., 2001; Sleeman et al., 2001; Wiedemann & Trueb, 2000). Half of D3 is
encoded in FGFR1, FGFR2 and FGFR3 by alternative exons. This gives rise to the ‘b’ and
‘c’ isoforms of the transmembrane receptor, which impart additional ligand selectivity
(Ornitz et al., 1996; Zhang et al., 2006). In addition, the tyrosine kinase FGFRs also bind
heparan sulfate (Kan et al., 1993; Powell, Fernig & Turnbull, 2002), which leads to one
ternary FGF-FGFR-heparan sulfate signalling structure (Schlessinger et al., 2000).
The FGFRs have varying degrees of selectivity for different FGFs, and the selectivity is
most conserved between FGFs in the same subfamily (Ornitz et al., 1996; Xu et al., 2013;
Zhang et al., 2006). FGF1 was recognised as a universal ligand for all the FGFRs,
while FGF2 and members of the FGF4 subfamily prefer to interact with FGFR 1c
(Zhang et al., 2006). For the ‘c’ isoform, the preference is FGFR 1c > FGFR 2c and
FGFR 3c, though the FGF4 subfamily ligands are clearly distinguished from the FGF1
subfamily in terms of their selectivity for FGFR 1b, which they do not bind, in contrast to
FGF1 and FGF2 (Ornitz et al., 1996; Zhang et al., 2006). Members of the FGF8 and
FGF9 subfamilies preferentially bind to FGFR 3c (FGFR 3c > FGFR 2c and 1c), while
members of FGF7 subfamily mainly bind FGFR 2b and 1b (Ornitz et al., 1996;
Zhang et al., 2006).
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KLOTHO CO-RECEPTORS
Klotho co-receptors (alpha and beta-Klotho/KLB) are type 1 transmembrane proteins
that define tissue specific activities of circulating endocrine FGFs (for reviews see Belov &
Mohammadi, 2013; Kuro-o, 2012; Martin, David & Quarles, 2012). aKlotho was originally
identified as an aging suppressor gene (Kuro-o et al., 1997). Findings that mice with
disrupted aKlotho expression displayed identical phenotypes to mice deficient in FGF23,
including shortened life span, growth retardation, muscle atrophy, vascular calcification
in the kidneys and disrupted serum phosphate balance, led to the discovery of aKlotho as
an obligatory co-receptor for FGF23 to bind and activate FGFR in the kidney (Kurosu
et al., 2006; Urakawa et al., 2006). Bone derived FGF23 acts in the aKlotho expressing
kidney to regulate vitamin D and phosphate homeostasis. Beta-Klotho (KLB) was
identified by its sequence homology to aKlotho (Ito et al., 2000), and later identified as a
co-receptor to allow FGF19 and −21 to bind and signal via their canonical FGFRs in bile
acid, glucose and lipid metabolism, respectively (Kharitonenkov et al., 2008; Kurosu et al.,
2007; Lin et al., 2007; Wu et al., 2007). The extracellular domains of Klotho co-receptors
are composed of two KL domains with sequence homology to beta-glucosidases (Ito et al.,
2000; Kuro-o et al., 1997). aKlotho also exists in a secreted form, either via alternative
splicing or via shedding of the extracellular domain by matrix metalloproteases. The
secreted form of Klotho has been shown to modulate glycans on Transient Receptor
Potential calcium channels TRPV5 and TRPV6 (Chang et al., 2005) and renal outer
medullary potassium channels (ROMK1) (Cha et al., 2009) in vitro, increasing their
cell-surface retention.
ASSEMBLY OF SIGNALLING COMPLEXES
The binding of the FGF ligand to its receptor with/without heparan sulfate (co-receptor)
causes the FGFR to dimerise. This in return enables phosphorylation of tyrosine residues
in the kinase activation loop and then of tyrosines that are docking sites for signalling
proteins (Goetz & Mohammadi, 2013). The latter activate most intracellular signalling
pathways, e.g. RAS-RAF-MAPK and PI3K-AKT, which regulate cell fate and specific cell
activities (Dorey & Amaya, 2010; Turner & Grose, 2010). Previous studies suggest
heparan sulfate (or its experimental proxy heparin) is required for many, but not all
signalling (Izvolsky et al., 2003). FGF signalling can be negatively regulated by
internalisation and degradation, as well as by transmembrane regulators, such as FGFRL1,
and intracellular ones, e.g. Sprouty and Spred (Casci, Vinos & Freeman, 1999;
Hacohen et al., 1998) and MAPK phosphatase 3 (Turner & Grose, 2010). Since there is a
great diversity of FGF ligands, FGFR isoforms and heparan sulfate structure and feedback
loops, the understanding of FGF signalling is still far from complete
(Dorey & Amaya, 2010).
ALTERNATIVE PARTNERS
FGFs and FGFRs interact directly with a large number of other partners, both
extracellularly and, following the internalisation of ligand-receptor complexes,
intracellularly. In some instances, e.g., FGF-2 binding integrins (Rusnati et al., 1997),
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these may be additional to the core complex of FGF, FGFR and heparan sulfate, but in
other cases, e.g., cadherins, these are orthogonal partners of one component of the core
FGF communication system, the FGFR (Doherty & Walsh, 1996). A partial list of the
alternative extracellular partners has been reviewed (Polanska, Fernig & Kinnunen, 2009b).
The intracellular partners and functions of FGF receptor-ligand complex components
translocated to the nucleocytoplasmic space have also been recently reviewed
(Coleman et al., 2014).
DIVERSIFICATION AND SWITCHING OF FUNCTION:
HINTS FROM C. ELEGANS
The functions of FGFs in mammals are very diverse, which reflects the expansion at the
molecular level of the FGF communication system that accompanied the evolution of
more complex animal body plans and physiology. In contrast C. elegans possesses one of
the simplest FGF communication systems, comprising two ligands, EGL-17
(Burdine et al., 1997) and LET-756 (Roubin et al., 1999), a single FGFR, EGL-15
(DeVore, Horvitz & Stern, 1995), and two orthologues of Klotho, KLO-1 and KLO-2
(Polanska et al., 2011). The EGL-15 receptor is alternatively spliced into an “A” and a “B”
isoform, resulting in structural differences in the extracellular domain of the receptor
between immunoglobulin domains I and II (Goodman et al., 2003). Work in C. elegans
provides an insight into the relation between the paracrine and endocrine activities of
FGFs and how heparan sulfate binding of FGFs may have changed during the expansion of
the family. This in turn provides one line of evidence to support the argument that we can
manipulate the FGF communication system therapeutically for patient benefit in repair
and metabolic scenarios, without undue risk of tumourigenesis.
The major functions of EGL-15 are paracrine in the cell migration of sex myoblasts
(DeVore, Horvitz & Stern, 1995), neural development (Bulow, Boulin & Hobert, 2004;
Fleming, Wolf & Garriga, 2005), and an early essential function (DeVore, Horvitz &
Stern, 1995) associated with physiological homeostasis (Huang & Stern, 2004;
Polanska et al., 2009a; Polanska et al., 2011). EGL-17/FGF acts as a chemoattractant to
guide sex myoblasts (Burdine, Branda & Stern, 1998), whereas LET-756/FGF is required
for the essential function of EGL-15, as animals lacking LET-756 arrest at early larval stage
(Roubin et al., 1999). In mammals, the “IIIb” and “IIIc” isoforms of FGFRs enable
ligand selectivity. In C. elegans this ligand to receptor pairing is determined in part by
tissue specific expression of the ligand and the “A” and “B” receptor isoforms
(Goodman et al., 2003; Lo et al., 2008). egl-15(5B) is predominantly expressed in the
hypodermis (Lo et al., 2008), where it mediates fluid homeostasis (Huang & Stern, 2004),
whereas egl-15(5A) isoform is expressed in the M lineage, which gives rise to the sex
myoblasts. Heterologous expression of egl-17, driven by the let-756 promoter, can
stimulate EGL-15(5B) and partially rescue the larval arrest phenotype of mutants lacking
LET-756, and expression of let-756 driven by egl-17 promoter can partially rescue sex
myoblast migration in EGL-15-deficient worms (Goodman et al., 2003). However,
although expression of either isoform of egl-15 in the hypodermis can mediate the fluid
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homeostasis phenotype, only EGL-15(5A) isoform can mediate sex myoblast
chemoattraction (Lo et al., 2008). Thus, the functional specificity of EGL-15 is determined
by the extracellular receptor isoform and the availability of the ligand. That there are
no multicellular organisms possessing just a single FGF ligand and one FGFR
isoform may reflect the importance of selective communication between tissue
compartments and of the ability of cells to switch the ligand channel they are tuned to
during development, without changing the receiver (the receptor kinase and
downstream signalling).
The role of EGL-15 in the regulation of C. elegans fluid homeostasis was first discovered
in mutants of a phosphatase, which acts downstream of EGL-15 (Kokel et al., 1998).
This phosphatase, CLR-1, acts as a negative regulator of EGL-15, and its absence leads to
excess EGL-15 activity and accumulation of fluid within the C. elegans pseudocoelom and
a clear (clr) phenotype. Excess EGL-15 activity and clear phenotype can also be achieved
by mutation of N-glycosylation sites in the extracellular domain of the EGL-15
receptor (Polanska et al., 2009a), as N-glycans act as a brake on receptor activation
(Duchesne et al., 2006). Under laboratory conditions C. elegansmust actively excrete fluid.
The major organs responsible for fluid balance are the hypodermis, which expresses
egl-15(5B) and klo-2 (Polanska et al., 2011) and the excretory canal, which is equivalent to
the mammalian kidney and expresses klo-1 (Polanska et al., 2011). Complete loss of
function of EGL-15 or LET-756 leads to loss of klo-1 expression and lack of functional
excretory canals (Polanska et al., 2011), a likely explanation of the early larval lethality of
the mutants defective of LET-756/EGL-15 signalling.
Thus, in C. elegans the same FGFs act as growth factors, morphogens and hormones,
whereas in mammals different FGFs perform the local and systemic functions. EGL-15
associates with Klotho co-receptors to mediate the fluid homeostasis function
(Polanska et al., 2011), which is entirely analogous to the mode of action of endocrine
FGFs in mammals. Although there is currently no genetic evidence to suggest that, as in
mammals, the assembly of a signalling complex of the C. elegans FGF ligands with EGL-15
and subsequent receptor activation would depend on the heparan sulfate co-receptor in
vivo, biochemical evidence shows that EGL-15/FGFR binds to heparin, a proxy for
heparan sulfate (Polanska et al., 2011), whereas sequence alignment of EGF-17 and
LET-756 to mammalian FGFs indicates that they possess heparan sulfate binding sites
(Xu et al., 2012). Importantly, binding to heparan sulfate would not preclude a hormone
homeostatic activity of C. elegans FGFs, since the range of the FGF would be significant
compared to the animal’s body size; C. elegans is small, (adult hermaphrodites ∼1 mm).
Thus, a reasonable hypothesis is that the communication system used in development,
LET-756 and EGL-15, is then co-opted into endocrine homeostasis. As animals grew
larger, this would no longer be possible. Diversification of the FGF family and weakening
of heparan sulfate binding would then allow both the growth factor/morphogen activity,
which is local due to heparan sulfate binding and the systemic hormonal activity to be
retained. In support of this idea is the demonstration that a human FGF-1 with its
primary heparan sulfate binding site mutated is reprogrammed from a growth factor to a
FGF-21 like hormone, controlling metabolism (Suh et al., 2014). A corollary is that the
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interaction of paracrine FGF ligands with heparan sulfate is one key to understanding
their function, their roles in disease and hence their therapeutic potential.
THE ASPECTS OF FGF ACTIVITIES LINKED
TO CANCERS
As noted above, a great deal of the early work on FGFs was from a cancer perspective,
though there was also a considerable effort directed at regeneration of damaged tissues.
While there is a bias in the scientific literature against reporting negative results, there are
some reports that showed in animal models and in clinical samples that there was not a
simple relationship between FGF ligand expression and tumour formation and
progression. Thus, when FGF-2 mRNA levels were analysed in a cohort of breast cancer
patients, elevated expression of FGF-2 mRNA correlated with a good prognostic outcome,
the opposite of the result expected from the naı¨ve perspective that “FGF2 = uncontrolled
growth + angiogenesis = cancer” (Anandappa et al., 1994). Similarly, in a syngeneic rat
model of breast cancer, overexpression of FGF2 failed to produce any metastases
(Davies et al., 1996). Given the difficulty in publishing negative results, there is likely a very
large body of work that demonstrates the absence of a direct association between the
expression of FGF ligands and cancer.
One reason is that, at least for FGF-1 and FGF-2, the ligand is often not limiting.
That is, there is a lot of ligand stored on heparan sulfate in tissues, which is then accessed
during repair. The discovery of the storage of FGF2 on heparan sulfate of extracellular
matrix (Vlodavsky et al., 1987) was followed by the realisation that stored FGF2 could
elicit a response at least in cultured cells (Presta et al., 1989) by diffusion within matrix
(Duchesne et al., 2012). The expression of other FGF ligands is, in contrast, often induced.
However, like FGF1 and FGF2, their activity is restricted, again through binding to
heparan sulfate and due to their selectivity for FGFRs. An important facet of development
and endogenous tissue repair is the mobilisation of FGF ligands by heparanase, a beta
glucuronidase, which cleaves heparan sulfate in NA and NAS domains, liberating growth
factor bound to an S domain (Arvatz et al., 2011; Barash et al., 2010; Kato et al., 1998;
Patel et al., 2010; Ramani et al., 2013). This plays a key role in many cancers
(Arvatz et al., 2011; Barash et al., 2010; Ramani et al., 2013). Therefore, the mechanistic
link between the FGF communication system and cancers is on the side of the
mobilisation of FGFs from such stores (particularly by heparanase, though proteases are
likely to also have a role) and of increases in the activity of FGFRs (Carter, Fearon &
Grose, 2015; Turner & Grose, 2010). Thus, in contrast to their ligands, the FGFRs are
established drivers of tumour progression. This arises from: activating mutations; isoform
switching, e.g., between the classic epithelial, FGFR2-IIIb isoform that binds FGF-7 family
members and FGFR2-IIIc isoform, that binds epithelial synthesized and mesenchymally
stored FGFs, including FGF-2 (Carter, Fearon & Grose, 2015; Turner & Grose, 2010).
FGFS AS REPAIR FACTORS
The use of FGFs to repair damaged tissue is a long-standing research area, however, until
recently in the West it was entirely confined to model systems. In Japan, alongside the
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cancer research track, a repair track leading to clinical applications was developed. In
contrast, in China FGF research was from the late 1980s spearheaded by the drive to
develop a biotechnology industry. This resulted in successful engineered production of
FGF1 and FGF2, (e.g., Wu et al., 2005; Wu et al., 2004; Yao et al., 2006; Zhao et al., 2004)
and a substantial effort in experimental medicine, including pharmacokinetic and toxicity
studies, (e.g., Li et al., 2002; Xu et al., 2003) to develop clinical applications. In much of
this work the original nomenclature, aFGF and bFGF is used for FGF1 and FGF2,
respectively; in the following summary of some of the clinical studies, the currently
accepted numerical nomenclature is employed. A major clinical focus in China has been
the use of FGF2 as a repair/regeneration factor in conditions as diverse as burns, chronic
wounds, oral ulcers, vascular ulcers, diabetic ulcers, pressure ulcers and surgical incisions.
As the Chinese studies are not generally accessible, we have summarised a number of these
below, alongside other work on similar conditions from Japanese research groups and the
few Western clinical trials. The very extensive preclinical literature is not covered.
THERAPEUTIC APPLICATIONS OF FGF2
FGFs have been investigated as therapeutic agents in a number of diseases, with varying
success. We outline some of the studies (Table 1), ranging from case series and
observational studies carried out prospectively (before treatment has been initiated) or
retrospectively (after treatment has been completed) or a combination of retrospective
and prospective approaches to well-designed randomised controlled studies carried out
prospectively. The quality of the studies is variable and with details of the FGFs used not
available in all instances (Table 1).
Burns
Liu, Jiang & Tan (2005) investigated the use of FGF2 in the treatment of burns and chronic
wounds. Patients were divided into a burn wound group (n = 62), a donor site wound
group (n = 36) and a chronic wound group (n = 65). The burn wounds included
superficial partial thickness burns and deep partial thickness burns; chronic wounds
included wounds that did not heal following routine treatment for 4 weeks, residual
granulation wounds, pressure ulcers, sinuses, and diabetic ulcers. The burn wound group
was treated with FGF2 in addition to the standard treatment. Self-control randomization
was applied to the burn wound group and donor site wound group, with comparisons of
the same subject before and after treatment. The control group was treated with equal
amounts of saline in addition to the standard treatment. The results showed that FGF2
significantly shortened the time to complete wound healing in the three wound groups
compared to the control group.
Guo (2006) randomly assigned 80 cases of deep partial thickness burn wounds to a
treatment group and a control group. In the treatment group, a gauze pad impregnated
with FGF2 solution was applied to the debrided wound, which was then covered with
another gauze pad containing 1% (w/w) silver sulfadiazine. Apart from substituting
normal saline for FGF2, the control group was subjected to the same treatment as the
FGF2 group. The results showed that the average healing time for superficial partial
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Table 1 Therapeutic applications of FGFs. Summary of the clinical uses of FGFs and the types of study.
FGF Disease/condition Author, year Type of study FGF preparation/
concentration
Outcome
FGF2 Burns and chronic
wounds
Liu, Jiang &
Tan, 2005
Prospective, self
controlled
randomisation study
FGF2 soaked gauze
(20,000 AU/100 cm2)
Healing time was significantly
reduced in the FGF2 treated
groups (burns and chronic
wounds) compared to the
control group.
FGF2 Burns Guo, 2006 Randomised controlled
study
FGF2 soaked gauze
(20,000 AU/100 cm2)
Healing time was significantly
reduced in the FGF2 treated
group.
FGF2 Burns (second degree) Akita et al., 2008 Randomised controlled
study
FGF2 Spray
(30 mg/30 cm2 area)
Healing time was significantly
reduced and quality of scar
improved in the FGF2 treated
group.
FGF2 Sutured wounds
(following skin tumour
removal)
Ono et al., 2007 Prospective,
non-randomised case
control study
Intradermal FGF2 injections
(low dose −0.1 mg FGF2 per
1 cm of wound, high dose
−1.0 mg FGF2 per 1 cm
wound) and high FGF2 rinses
(0.1 mL of 10 mg/mL
FGF2 solution per 1 cm
wound)
Scarring was significantly
reduced in the FGF2 treated
groups (low and high doses of
FGF2).
FGF2 Donor sites (split
thickness skin grafts)
Xu, Li & Fan, 2000 Randomised self-
controlled trial
FGF2 soaked gauze
(150 U/cm2 for the first 3 days
followed 100 U/cm2
subsequently)
FGF2 significantly reduced
healing time and improved
quality of the scar in the
treatment group.
FGF2 Avulsion wounds/
full-thickness
skin graft
Matsumine, 2015 Prospective, case series FGF2 spray (1 mg/cm2 of
graft bed)
FGF2 application resulted in
wound healing with flexible
scars in all cases.
FGF2 Sutured wounds
(cosmetic surgery)
Lu, Jin & Pang, 2006 Observational study FGF2 soaked gauze
(concentration details not
available)
FGF2 application resulted in a
significantly shorter healing
time and better quality
of scar.
FGF2 Wound dehiscence
following Caesarean
section
Chen & He, 2004 Randomised controlled
study
FGF2 spray (2–4 mL per
application; details of
concentration not available)
FGF2 resulted in a significantly
shorter healing time in wounds
<5 cm in the treatment group.
FGF2 Tibial shaft fractures Kawaguchi et al.,
2010
Randomised, double
blind, placebo-controlled
study
2 percutaneous injections of
hydrogel (0.5 mL each,
containing 0, 0.4, or 1.2 mg
of FGF2)
FGF2 accelerated healing of
tibial fractures in the
treatment groups.
FGF2 Traumatic skin ulcers Zang, Zha &
Yao, 2005
Randomised controlled
study
FGF2 biological protein
sponge (concentration
details not available)
FGF2 application resulted
in a significantly higher
healing rate in the
treatment group.
FGF2 Recurrent aphthous
stomatitis
Jiang et al., 2013 Double blind, randomised
controlled trial
Paste A contained
Diosmectite (DS) −80 mg/g
and FGF2 −10 mg/g. Paste C
(FGF2 paste) primarily
contained FGF2 (10 mg/g)
Paste A (DS + FGF2)
significantly reduced ulcer pain
scores and ulcer size.
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thickness burn wounds in the FGF2-treated group was significantly shorter as compared
to the control group (9.51 ± 1.86 days vs. 12.43 ± 2.03 days, p < 0.05). Similarly, the
healing time in the deep partial thickness burn wounds in the FGF2 treatment group
was significantly shorter than the control group (18.36 ± 4.87 days vs. 22.35 ± 5.60 days,
p < 0.01).
FGF2 has also been shown to accelerate healing and improves scar quality in second-
degree burns (Akita et al., 2008). Since the speed of wound healing is an important factor
influencing the outcome of treatment, as well as a crucial step in burn wound treatment,
and the quality of wound healing has a direct bearing on the quality of life of patients,
FGF2 clearly has clinical efficacy in a variety of burn settings.
Table 1 (continued).
FGF Disease/condition Author, year Type of study FGF preparation/
concentration
Outcome
FGF2 Periodontal
regeneration
Kitamura et al.,
2011
Double blind, randomised
controlled trial
0.2%, 0.3%, or 0.4% FGF2 gel
for local application
The periodontal fill was
significantly higher in the FGF2
treated group.
FGF2 Aphthous ulcers Ren & Shun, 2002 Randomised, double-
blinded, controlled trial
FGF2 spray
(300 AU/application,
4 times/day)
FGF2 significantly reduced the
ulcer healing time in the
treatment group.
FGF7 Oral mucositis
(Chemo-radiotherapy)
Goldberg et al., 2013 Retrospective
observational study
Three daily doses of FGF7
(60 mg/kg/day) were given
prior to transplant admission
with the third dose given no
fewer than 24 hours prior to
administration of
chemotherapy or
radiotherapy. Six hours after
stem cell infusion, patients
received three further
daily doses of FGF7
(60 mg/kg/day).
FGF7 significantly reduced the
number of days of total
parenteral nutrition, patient-
controlled analgesia and length
of hospital stay in patients
receiving total body
irradiation.
FGF2 Traumatic perforations
of the tympanic
membrane
Lou and Wang, 2013 Prospective, sequential
allocation, three-armed,
controlled clinical study
0.25 mL (4–5 drops) of FGF2
(21,000 IU/5 mL) solution
Average closure time was
significantly shorter in the
FGF2 application group.
FGF2 Pressure ulcers Robson et al., 1992 Randomised, blinded,
placebo-controlled trial
FGF spray (concentrations of
100 mg/mL, 500 mg/mL, or
1000 mg/mL
FGF2 resulted in a significantly
higher number of patients with
70% decrease in size of the
ulcer in the FGF2 treated
group.
FGF2 Diabetic ulcer Uchi et al., 2009 Randomised, double
blinded, dose-ranging,
placebo-controlled trial
FGF2 solution (0.01% and
0.001% w/v)
Cure rates were significantly
higher in the 0.01% w/v FGF2
treated group.
FGF2 Critical limb
ischaemia
Kumagai et al.,
2015
Phase I-IIa trial 200 mg of FGF2 incorporated
gelatin hydrogel microspheres
injected intramuscularly into
the ischemic limb
Transcutaneous pressure,
distance walked in 6 minutes,
rest pain scale and cyanotic
pain scale showed
significant improvement
at 24 weeks post-treatment
with FGF2 as compared
to pre-treatment.
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Surgical wounds
Surgical incisions
Surgical incisions leave scars as part of the normal healing process. These scars vary from
being narrow, wide, atrophied or hypertrophic and sometimes cause medical problems, or
social ones, because of their cosmetic appearance (Rockwell, Cohen & Ehrlich, 1989).
A study by Ono et al. (2007) examined the effect of local administration of FGF2 on
sutured wounds. FGF2 was injected into the dermis of the wound margins using a needle
immediately after the skin was sutured following an operation. None of the patients
treated with FGF2 had hypertrophic scars compared to the control group and scarring
was significantly lower in the groups treated with FGF2, as compared to the
control group.
Skin graft wounds
Healing of the donor site wounds, created after skin graft harvesting, involves the
regeneration of epithelial cells in the residual skin appendages (Metcalfe & Ferguson,
2007). Early healing of donor site wounds helps to reduce trauma, thereby facilitating the
treatment of the primary disease.
Xu, Li & Fan (2000) conducted a clinical study to examine the efficacy of topical
application of FGF2 on 48 donor site wounds in 34 patients, which were created by
harvesting intermediate split thickness skin grafts. The wounds before treatment served as
self-controls. Following the harvesting of the skin grafts, the wound surface was evenly
coated with FGF2 using a cotton swab, covered with vaseline gauze, and dressed. The
control wounds were smeared only with the vehicle without FGF2, the rest of the topical
treatment procedures being identical as the treatment group. The results showed healing
time in wounds treated with FGF2 was 2.8 days shorter compared to control wounds
(p < 0.01). Moreover, FGF2-treated wounds appeared flatter, smoother and firmer and
were difficult to tear off, as compared to the control wounds. The use of FGF2 yielded no
adverse reactions.
Full thickness skin grafts in avulsion injuries
Matsumine (2015) described the topical use of FGF2 in the treatment of avulsion
wounds (as a result of skin and/or underlying tissue torn away due to trauma) with
full thickness grafts using the avulsed skin. The contaminated subcutaneous fat
tissue on the inside of skin was excised and the avulsed skin was processed into a
full-thickness skin graft. Drainage holes (5–10 mm in diameter) were made on the graft
to prevent seroma and haematoma formation. FGF2 was sprayed onto the graft
bed, followed by application of the graft. Skin grafts that did not take were scraped
away, preserving the revascularized viable dermis where possible. FGF2 was then
sprayed again onto this surface to promote epithelialization (proliferation of
epithelial cells to cover the wound). Wound closure was achieved in all cases with
conservative therapy. This procedure promoted wound healing with the formation of
good-quality, flexible scars and prevented postoperative ulcer formation and
scar contracture.
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Cosmetic surgical incisions
Wound healing quality is important in the success of cosmetic surgery. Lu, Jin & Pang
(2006) examined the effects of FGF2 on wound repair in 60 female patients who
underwent cosmetic surgery. All surgical incisions were clean cuts, and self-controls
(another incisional wound on the same patient) were used. In the treatment group FGF2
was applied once daily until removal of stitches, starting with the first postoperative day.
Wounds due to laser resurfacing were smeared with FGF2 twice daily until natural
decrustation occurred. The control group was subjected to conventional dressing change
until removal of stitches. The results showed that in the FGF2 group whose wounds
resulted from laser resurfacing, the average decrustation time was significantly shorter
than in the control group (6.2 days vs. 8.1 days, p < 0.05). The FGF2-treated groups
showed good healing. In addition, exudate and swelling post surgery were milder in the
FGF2 groups than in the control group. There were no adverse reactions in the FGF2
groups. Quality of wound healing was superior and the healing time was shorter in the
FGF2 groups as compared to the control group, indicating that FGF2 has a favourable
effect on cosmetic surgical incision healing.
Obstetric wounds
Dehiscence of caesarean section incisions may occur in the form of a superficial
dehiscence, in which the skin and subcutaneous fat layer break open, most often due to fat
liquefaction caused by subcutaneous fat hypertrophy in pregnant women. In addition, a
long trial of labour, excessive vaginal examinations, vaginitis, and intrauterine infections
may potentially lead to an increase in infected incisions. Anaemia, hypoproteinemia,
malnutrition, and diabetes in the perinatal period can result in poor healing capacities of
local tissues. These factors can adversely affect wound healing extending hospital stay, and
increasing costs.
Chen & He (2004) randomly assigned 60 patients with wound dehiscence following a
caesarian section to two groups: an observation group and a control group. After
debridement of the wounds, FGF2 was sprayed on the wounds and they were sutured the
next day. Wound dressings were changed regularly. The control group was treated
similarly, but without the use of FGF2 spray. Healing time was significantly shorter in
patients with dehiscence measuring 5 cm in size or below treated with FGF2 compared to
the control group (6.8 ± 1.5 days vs. 11.2 ± 1.2, p < 0.01). In contrast, in patients with
dehiscence measuring 5 cm and above secondary suturing was undertaken. In this
instance there was no significant difference in the FGF2 treated group compared to their
respective control group (7.6 ± 1.0 days vs. to 7.4 ± 0.8, p > 0.05); it is likely that this
control group’s shortened healing time, compared to the control group with dehiscence
measuring 5 cm or less, was due to secondary suturing.
Orthopaedic trauma wounds
FGF signalling plays an important role in skeletal development (Su, Du & Chen, 2008).
Tissue necrosis and infection of fresh skin defect wounds, grafted flaps, and skin grafts
occurs following orthopaedic trauma surgery. In order to shorten the healing time and
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reduce the rate of skin re-grafting, FGF2 has been directly applied to fresh and debrided
necrotic wounds.
Kawaguchi et al. (2010) conducted a randomised, placebo-controlled trial, investigating
the direct application of FGF2 in a gelatin hydrogel on traumatic tibial fractures.
A single injection of gelation containing placebo or low dose FGF (0.8 mg) or high dose
FGF (2.4 mg) was administered into the fracture gap at the end of intramedullary nailing
surgery. Radiographic bone union was significantly higher in the FGF2 treated groups,
with no significant difference between the two FGF2 dosage groups.
Zang, Zha & Yao (2005) investigated the use of a FGF2 biological protein sponge for
traumatic ulcers. A sterile FGF2 biological protein sponge was applied to traumatic skin
ulcers in 20 patients. The results showed that the wound-healing rate within 3 weeks was
95% in the FGF group and 55% in the control group, and that the rate of skin re-grafting
in the FGF2 group was significantly lower than that in the control group. Wound
secretions and peri-wound inflammation were markedly less severe in the FGF2 group as
compared to the control group. No obvious adverse reactions were reported in either
group. These data indicate that FGF2 biological protein sponges may promote the healing
of traumatic ulcers and shorten healing time.
Oral diseases
Oral ulcers are a common disease of the oral mucosa and tend to recur. Pathologically,
ulcers of oral mucosa are mainly characterized by dissolution, rupture, and shedding of
local oral mucosal epithelium to form non-specific ulcers.
A study by Jiang et al. (2013) investigated the use of topical application of diosmectite
(DS; an insoluble silicate) and FGF2 paste in the treatment of minor recurrent aphthous
stomatitis (repeated formation of benign, non-infectious ulcers in the mouth). Four
pastes, containing FGF2 and DS, DS alone, FGF2 alone, and vehicle only, were used in
129 participants. DS-FGF2 significantly lowered ulcer pain scores (p < 0.05 for days 3, 4,
5, and 6) as compared to the other pastes. Ulcer size was significantly reduced (p < 0.05 for
days 2, 4, and 6) in this group. No obvious adverse drug effects were observed.
Kitamura et al. (2011) conducted a multicentre, randomised, double blind, placebo-
controlled trial, in accordance with Good Clinical Practice guidelines, to clarify the
efficacy and safety of FGF2 use in periodontal regeneration. The percentage of bone fill
was significantly higher in the FGF2 treatment group as compared to the ‘vehicle alone’
group at 36 weeks. Also, there were no serious adverse effects in the treatment group.
Radiotherapy is commonly used to treat head and neck cancer. However, when the
radiation dose rises to about 20 Gy–30 Gy, acute inflammation of the oral mucosa usually
occurs, the symptoms of which include, among other things, oropharyngeal pain, and oral
ulcers associated with oedema or pseudomembrane formation. Food intake is affected as a
result. Moreover, the severity of the symptoms increases with the radiation dose. Patients
who experience serious symptoms have to suspend the treatment, and the final efficacy of
the treatment is thus impaired (Vera-Llonch et al., 2006; Worthington et al., 2011).
Myeloablative allogeneic haemopoietic stem cell transplantation is an established
treatment for haematologic malignancies and oral mucositis is a known complication
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arising from high dose chemotherapy and radiation therapy. Goldberg et al. (2013)
performed a retrospective study investigating the use of peritransplant Palifermin
(recombinant FGF7) and found that it significantly reduced the number of days of total
parenteral nutrition, patient-controlled analgesia and length of hospital stay in patients
receiving total body irradiation as compared to those receiving chemotherapy based
transplantation.
Ren & Shun (2002) conducted a double-blind study, in which 121 patients with mild
aphthous ulcers (mouth ulcers) were randomly assigned to either a FGF2 group (n = 63)
or a control group (n = 58). In the FGF2 group, FGF2 was locally sprayed onto the surface
of ulcers; in the control group, 0.2% (w/v) chlorhexidine solution was sprayed on the
ulcers. The results showed that the effective rate at day 3 was 90.48% in the FGF2 group
and 60.34% in the control group (p < 0.05). Meanwhile, the average healing time of ulcers
was significantly shorter in the FGF2 group than in the control group (Chi square test;
p < 0.05). The results show that FGF2 exhibits significant efficacy for mild recurrent
aphthous oral ulcers.
Tympanic membrane perforations
While most traumatic perforations of the tympanic membrane tend to heal
spontaneously, large perforations may often fail to do so. The management of these is still
open to debate, with a number of specialists recommending an early myringoplasty to
improve outcomes (Conoyer, Kaylie & Jackson, 2007). Lou & Wang (2013) undertook a
prospective, sequential allocation, three-armed, controlled clinical study to compare
perforation edge approximation vs. FGF2 application in the management of traumatic
perforations of the tympanic membrane. Patients were divided into 3 groups: no
intervention (n = 18), edge approximation (n = 20) and direct application of FGF2
(n = 20). Otoscopy was performed before and after treatment and response measurements
were made, such as closure rate, closure time and rate of otorrhoea. Perforation
closure was significantly higher in the FGF2 group (100%) as compared to the edge
approximation (60%) and control (56%) groups (p < 0.05). Average closure time
was significantly shorter in the FGF2 treatment group (12.4 ± 3.6 days), as compared
to the edge approximation (46.3 ± 8.7 days) and control (48.2 ± 5.3 days)
groups (p < 0.05). Lou, Wang & Yu (2014) showed that a lower dose (0.1 to 0.15 mL)
of FGF2 (21,000 IU/5 mL) was more effective than a higher dose (0.25 to 0.3 mL).
Hakuba et al. (2010) demonstrated that FGF2 combined with atelocollagen was an
effective treatment for chronic tympanic membrane perforations.
Pressure ulcers
Treatment of pressure ulcers is a major problem for clinical care. Pressure ulcers can
increase patients’ suffering, extend the duration of illness, and, when serious, may even
prove to be life threatening due to sepsis resulted from secondary infection. Commonly
used treatments over the years have included innovative mattresses, ointments, creams,
solutions, dressings, ultrasonography, ultraviolet heat lamps, and surgery.
Robson et al. (1992) investigated the role of FGF2 in the treatment of pressure ulcers
with a randomized, blinded, placebo-controlled trial, which enrolled 50 patients with
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pressure ulcers varying in size from 10 to 200 cm3. The results showed that, compared
with placebo-treated patients, the number of FGF2-treated patients whose ulcers shrank
by 70% increased significantly (60/100 vs. 29/100, p = 0.047). Histological analysis of
FGF2-treated wounds showed a significant increase in the number of fibroblasts and
capillaries.
Diabetic foot
Diabetic foot is a serious complication of diabetes and an important cause of diabetes-
related disability. When diabetic foot develops, the patient’s feet are prone to injury,
infection, ulcers and gangrene.
Uchi et al. (2009) conducted a randomized, double blind, dose-ranging, placebo-
controlled trial to examine the clinical efficacy of FGF2 in the treatment of diabetic ulcers.
Patients’ diabetic ulcers were randomized into a placebo group (n = 51), a 0.001% (w/v)
FGF2 treatment group (n = 49) and a 0.01% (w/v) FGF2 treatment group (n = 50), with
the primary outcome being the percentage of patients showing a 75% or greater reduction
in the area of ulcer. The area of ulcer decreased by 75% or more in 57.5% (27/47), 72.3%
(34/47), and 82.2% (37/45) in the placebo, 0.001% (w/v) FGF2 and 0.01% (w/v) FGF2
groups, with significant differences between the 0.01% (w/v) FGF2 treatment and
placebo groups (p = 0.025). Cure rates were 46.8%, 57.4%, and 66.7% in the placebo,
0.001% (w/v) FGF and 0.01% (w/v) FGF2 groups. This trial showed that FGF2 accelerates
healing of diabetic ulcers.
Critical limb ischaemia
Kumagai et al. (2015) conducted a phase I-IIa trial, investigating the use of a sustained
release system of FGF2 using a biodegradable gelatin hydrogel in patients with critical
limb ischaemia. The measured transcutaneous pressure, distance walked in 6 minutes, rest
pain scale and cyanotic pain scale showed significant improvement at 24 weeks post-
treatment as compared to pre-treatment.
Other applications
Repair of cerebrospinal fluid leakage is difficult, which is especially so when a large fistula,
with concomitant mucosal damage and infection, has developed from repeated
transsphenoidal operations. Kubo et al. (2005) reported a 27-year-old woman with
intractable cerebral spinal fluid rhinorrhea who had undergone repeated operations for a
relapsing Rathke’s cleft cyst. They repaired the sellar floor defect using mucosal flaps via an
endonasal endoscopic approach and occluded the fistula by applying FGF2 to the area to
promote granulation. FGF2 was repeatedly applied endoscopically to the mucosal flaps,
which turned into granulation-like tissue, and complete mucosal covering was attained.
This method of treating the intractable fistula with mucosal flaps and FGF2 may present a
new clinical application of FGF2 and should be examined in a large number of patients in
the future.
The mucosa of the vocal folds atrophies with age causing glottal insufficiency, which is
difficult to treat. Hirano et al. (2008) reported a case of a patient, with atrophied vocal
folds, who was treated with FGF2 injections into the folds under local anaesthesia.
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The atrophy of the vocal fold improved within a week following the injection and the
glottic gap disappeared. Aerodynamic and acoustic parameters also showed remarkable
improvement, when measured. Subsequently, a trial (Hirano et al., 2012) demonstrated
that this therapy might be safe and effective in the treatment of age-related vocal fold
atrophy.
PROSPECTS
In Europe and N America, the substantial investment by cancer sources into growth
factors such as the FGFs has resulted in oncology directed clinical translation, in the form
of FGFR inhibitors (Carter, Fearon & Grose, 2015; Turner & Grose, 2010). In contrast, the
biotechnology drive in China resulted in exploitation of engineered FGF ligands to repair
and regenerate damaged tissue in a wide range of settings, with Japan having clinical
experience in both areas. We have not been able to identify reports of adverse reactions to
treatment with FGF ligands–these undoubtedly occur, but the frequency or their severity
may be too low and confounded by the underlying medical condition, such that they
have not appeared in the case literature. In any event, it is clear that the Chinese and
Japanese experience with FGF ligands as biologics in repair and regeneration clinical
scenarios has been an outstanding success; FGFs in China have progressed from
engineered biotechnology products (Wu et al., 2005; Wu et al., 2004; Yao et al., 2006;
Zhao et al., 2004) to the Chinese (Pharmacopeia, 2015). Many of the conditions, e.g.,
diabetic foot, make important and growing demands on healthcare systems and carry
considerable socioeconomic costs. Thus, Western medical practice may usefully follow
where China and Japan have led and explore the use of FGF ligands as repair and
regeneration agents. The realisation of the clinical potential of the FGF communication
system outside of oncology has been long overdue in the West. However, Western industry
is now actively engaged in the development of FGF therapeutics. This includes
development of FGF21 based therapeutics for metabolic syndrome (Kharitonenkov &
Shanafelt, 2008; Kharitonenkov & Shanafelt, 2009; Zhang & Li, 2014), of FGF7 for oral
mucositis (Goldberg et al., 2013) and of FGF18 in osteoarthritis (Carli et al., 2012; Mori
et al., 2014), it is likely that we will see FGF biologics in clinical use in the West, as well as
in the East. Indeed, the use of FGF18 to treat osteoarthritis is progressing through clinical
trials (Lohmander et al., 2014).
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